NeuroScientific Biopharmaceuticals Ltd. (NeuroScientific or the company) announced that it has filed a new patent, entitled "Neuroprotective compositions and methods (The Australian provisional application number is 2022903564, establishing the priority date of 24 November 2022). An in vitro study using cultured rat cortical neurons was undertaken to evaluate the effect of treatments on neuron survival, neurite length and area of myelin sheath, all of which are key mechanisms involved in Multiple Sclerosis. Two dose levels of EmtinB® alone, two dose levels of Copaxone® alone and two different combinations of EmtinB® + Copaxone® were evaluated, as per the table below, to determine if a synergistic effect occurs when the two products are co-administered.

Treatment with Copaxone® alone at 3µg/mL and 10µg/mL is not able to modulate cortical neurons survival but significantly increases, at both dose levels, the neurites length and a high dose only significantly improves myelin formation. Treatment with EmtinB ® alone promotes cortical neuron survival and myelin sheath formation with significant effect at the higher dose level. Furthermore, EmtinB ® tends to increase neurites length of cortical neurons with a significant effect observed at the low dose level.

It was only the co-treatment of EmtinB® and Copaxone® that significantly promotes neurite length, cortical neuron survival and myelin sheath formation around cortical neurons in concert. This effect seems to be synergistic since the combination of EmtinB® at 50µg/mL and Copaxone® at 3µg/mL gives a statistically significant effect in all three areas. This three- pronged effect is not observed when either compound is applied alone.

These data suggests that EmtinB® may provide additional therapeutic benefit to Copaxone®, one of Teva's most successful drugs in its portfolio.